Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer
- 30 April 2022
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 23 (5) , e317-e320
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (U10CA180820, U10CA180821, U10CA180868, U10CA180882, U10CA180888, UG1CA232760, UG1CA233180, UG1CA233191, UG1CA233253, UG1CA233277)
- Foundation for the National Institutes of Health
- National Cancer Institute
This publication has 13 references indexed in Scilit:
- Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC TrialJournal of Thoracic Oncology, 2021
- Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patientsProceedings of the National Academy of Sciences, 2020
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With NivolumabJAMA Oncology, 2019
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2019
- Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancerBritish Journal of Cancer, 2019
- Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized StudyJournal of Clinical Oncology, 2019
- Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trialThe Lancet, 2019
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenNew England Journal of Medicine, 2018
- Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic RadiotherapyJAMA Oncology, 2018
- A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell CarcinomaClinical Cancer Research, 2017